Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

The α2,3-selective potentiator of GABAA receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in rats.

Witkin JM, Cerne R, Davis PG, Freeman KB, do Carmo JM, Rowlett JK, Methuku KR, Okun A, Gleason SD, Li X, Krambis MJ, Poe M, Li G, Schkeryantz JM, Jahan R, Yang L, Guo W, Golani LK, Anderson WH, Catlow JT, Jones TM, Porreca F, Smith JL, Knopp KL, Cook JM.

Pharmacol Biochem Behav. 2019 Feb 27. pii: S0091-3057(18)30634-8. doi: 10.1016/j.pbb.2019.02.013. [Epub ahead of print]

PMID:
30825491
2.

Evaluation of 5-HT7 receptor antagonism for the treatment of anxiety, depression, and schizophrenia through the use of receptor-deficient mice.

Balcer OM, Seager MA, Gleason SD, Li X, Rasmussen K, Maxwell JK, Nomikos G, Degroot A, Witkin JM.

Behav Brain Res. 2019 Mar 15;360:270-278. doi: 10.1016/j.bbr.2018.12.019. Epub 2018 Dec 10.

PMID:
30543903
3.

Effects of 5-HT7 receptor antagonists on behaviors of mice that detect drugs used in the treatment of anxiety, depression, or schizophrenia.

Maxwell J, Gleason SD, Falcone J, Svensson K, Balcer OM, Li X, Witkin JM.

Behav Brain Res. 2019 Feb 1;359:467-473. doi: 10.1016/j.bbr.2018.11.019. Epub 2018 Nov 22.

PMID:
30471311
4.

Pharmacological characterization of the neurotrophic sesquiterpene jiadifenolide reveals a non-convulsant signature and potential for progression in neurodegenerative disease studies.

Witkin JM, Shenvi RA, Li X, Gleason SD, Weiss J, Morrow D, Catow JT, Wakulchik M, Ohtawa M, Lu HH, Martinez MD, Schkeryantz JM, Carpenter TS, Lightstone FC, Cerne R.

Biochem Pharmacol. 2018 Sep;155:61-70. doi: 10.1016/j.bcp.2018.06.022. Epub 2018 Jun 22.

PMID:
29940173
5.

Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABAA receptors: Improved bioavailability enhances anticonvulsant efficacy.

Witkin JM, Smith JL, Ping X, Gleason SD, Poe MM, Li G, Jin X, Hobbs J, Schkeryantz JM, McDermott JS, Alatorre AI, Siemian JN, Cramer JW, Airey DC, Methuku KR, Tiruveedhula VVNPB, Jones TM, Crawford J, Krambis MJ, Fisher JL, Cook JM, Cerne R.

Neuropharmacology. 2018 Jul 15;137:332-343. doi: 10.1016/j.neuropharm.2018.05.006. Epub 2018 May 3.

PMID:
29778948
6.

An antidepressant-related pharmacological signature for positive allosteric modulators of α2/3-containing GABAA receptors.

Methuku KR, Li X, Cerne R, Gleason SD, Schkeryantz JM, Tiruveedhula VVNPB, Golani LK, Li G, Poe MM, Rahman MT, Cook JM, Fisher JL, Witkin JM.

Pharmacol Biochem Behav. 2018 Jul;170:9-13. doi: 10.1016/j.pbb.2018.04.009. Epub 2018 Apr 30.

PMID:
29715490
7.

Chronic pain impairs cognitive flexibility and engages novel learning strategies in rats.

Cowen SL, Phelps CE, Navratilova E, McKinzie DL, Okun A, Husain O, Gleason SD, Witkin JM, Porreca F.

Pain. 2018 Jul;159(7):1403-1412. doi: 10.1097/j.pain.0000000000001226.

PMID:
29578947
8.

Negative allosteric modulation of alpha 5-containing GABAA receptors engenders antidepressant-like effects and selectively prevents age-associated hyperactivity in tau-depositing mice.

Xu NZ, Ernst M, Treven M, Cerne R, Wakulchik M, Li X, Jones TM, Gleason SD, Morrow D, Schkeryantz JM, Rahman MT, Li G, Poe MM, Cook JM, Witkin JM.

Psychopharmacology (Berl). 2018 Apr;235(4):1151-1161. doi: 10.1007/s00213-018-4832-9. Epub 2018 Jan 26.

PMID:
29374303
9.

Targeted Blockade of TARP-γ8-Associated AMPA Receptors: Anticonvulsant Activity with the Selective Antagonist LY3130481 (CERC-611).

Witkin JM, Schober DA, Gleason SD, Catlow JT, Porter WJ, Reel J, Jin X, Hobbs J, Gehlert D, Gernert DL, Gardinier KM, Kato AS, Ping X, Smith JL.

CNS Neurol Disord Drug Targets. 2017;16(10):1099-1110. doi: 10.2174/1871527316666171101132047.

PMID:
29090671
10.

Electroencephalographic, cognitive, and neurochemical effects of LY3130481 (CERC-611), a selective antagonist of TARP-γ8-associated AMPA receptors.

Witkin JM, Li J, Gilmour G, Mitchell SN, Carter G, Gleason SD, Seidel WF, Eastwood BJ, McCarthy A, Porter WJ, Reel J, Gardinier KM, Kato AS, Wafford KA.

Neuropharmacology. 2017 Nov;126:257-270. doi: 10.1016/j.neuropharm.2017.07.028. Epub 2017 Jul 28.

PMID:
28757050
11.

Further evaluation of the potential anxiolytic activity of imidazo[1,5-a][1,4]diazepin agents selective for α2/3-containing GABAA receptors.

Witkin JM, Cerne R, Wakulchik M, S J, Gleason SD, Jones TM, Li G, Arnold LA, Li JX, Schkeryantz JM, Methuku KR, Cook JM, Poe MM.

Pharmacol Biochem Behav. 2017 Jun;157:35-40. doi: 10.1016/j.pbb.2017.04.009. Epub 2017 Apr 22.

12.

Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors.

Witkin JM, Rorick-Kehn LM, Benvenga MJ, Adams BL, Gleason SD, Knitowski KM, Li X, Chaney S, Falcone JF, Smith JW, Foss J, Lloyd K, Catlow JT, McKinzie DL, Svensson KA, Barth VN, Toledo MA, Diaz N, Lafuente C, Jiménez A, Benito A, Pedregal C, Martínez-Grau MA, Post A, Ansonoff MA, Pintar JE, Statnick MA.

Pharmacol Res Perspect. 2016 Nov 7;4(6):e00275. doi: 10.1002/prp2.275. eCollection 2016 Dec.

13.

Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanism.

Kato AS, Burris KD, Gardinier KM, Gernert DL, Porter WJ, Reel J, Ding C, Tu Y, Schober DA, Lee MR, Heinz BA, Fitch TE, Gleason SD, Catlow JT, Yu H, Fitzjohn SM, Pasqui F, Wang H, Qian Y, Sher E, Zwart R, Wafford KA, Rasmussen K, Ornstein PL, Isaac JT, Nisenbaum ES, Bredt DS, Witkin JM.

Nat Med. 2016 Dec;22(12):1496-1501. doi: 10.1038/nm.4221. Epub 2016 Nov 7.

PMID:
27820603
14.

Hedonic and motivational responses to food reward are unchanged in rats with neuropathic pain.

Okun A, McKinzie DL, Witkin JM, Remeniuk B, Husein O, Gleason SD, Oyarzo J, Navratilova E, McElroy B, Cowen S, Kennedy JD, Porreca F.

Pain. 2016 Dec;157(12):2731-2738.

15.

Discovery of the First α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antagonist Dependent upon Transmembrane AMPA Receptor Regulatory Protein (TARP) γ-8.

Gardinier KM, Gernert DL, Porter WJ, Reel JK, Ornstein PL, Spinazze P, Stevens FC, Hahn P, Hollinshead SP, Mayhugh D, Schkeryantz J, Khilevich A, De Frutos O, Gleason SD, Kato AS, Luffer-Atlas D, Desai PV, Swanson S, Burris KD, Ding C, Heinz BA, Need AB, Barth VN, Stephenson GA, Diseroad BA, Woods TA, Yu H, Bredt D, Witkin JM.

J Med Chem. 2016 May 26;59(10):4753-68. doi: 10.1021/acs.jmedchem.6b00125. Epub 2016 Apr 29.

PMID:
27067148
16.

Inquiries into the Biological Significance of Transmembrane AMPA Receptor Regulatory Protein (TARP) γ-8 Through Investigations of TARP γ-8 Null Mice§.

Gleason SD, Kato A, Bui HH, Thompson LK, Valli SN, Stutz PV, Kuo MS, Falcone JF, Anderson WH, Li X, Witkin JM.

CNS Neurol Disord Drug Targets. 2015;14(5):612-26.

PMID:
25921737
17.

Obituary: J. David LEander, Ph.D. : (April 8, 1944-November 14, 2014).

Witkin JM, Gleason SD, Carter RB, Dykstra LA.

Psychopharmacology (Berl). 2015 Apr;232(7):1175-6. doi: 10.1007/s00213-015-3885-2. Epub 2015 Feb 21. No abstract available.

PMID:
25697862
18.

Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models.

Zwart R, Sher E, Ping X, Jin X, Sims JR Jr, Chappell AS, Gleason SD, Hahn PJ, Gardinier K, Gernert DL, Hobbs J, Smith JL, Valli SN, Witkin JM.

J Pharmacol Exp Ther. 2014 Oct;351(1):124-33. doi: 10.1124/jpet.114.212779. Epub 2014 Jul 15.

PMID:
25027316
19.

mGlu2/3 agonist-induced hyperthermia: an in vivo assay for detection of mGlu2/3 receptor antagonism and its relation to antidepressant-like efficacy in mice.

Gleason SD, Li X, Smith IA, Ephlin JD, Wang XS, Heinz BA, Carter JH, Baez M, Yu J, Bender DM, Witkin JM.

CNS Neurol Disord Drug Targets. 2013 Aug;12(5):554-66.

PMID:
23574174
20.

Further evaluation of the neuropharmacological determinants of the antidepressant-like effects of curcumin.

Witkin JM, Leucke S, Thompson LK, Lynch RA, Ding C, Heinz B, Catlow JT, Gleason SD, Li X.

CNS Neurol Disord Drug Targets. 2013 Jun;12(4):498-505.

PMID:
23574162
21.

In vivo occupancy of dopamine D3 receptors by antagonists produces neurochemical and behavioral effects of potential relevance to attention-deficit-hyperactivity disorder.

Barth V, Need AB, Tzavara ET, Giros B, Overshiner C, Gleason SD, Wade M, Johansson AM, Perry K, Nomikos GG, Witkin JM.

J Pharmacol Exp Ther. 2013 Feb;344(2):501-10. doi: 10.1124/jpet.112.198895. Epub 2012 Nov 29.

PMID:
23197772
22.

Multiple dopamine receptors mediate the discriminative stimulus effects of dihydrexidine in rats.

Gleason SD, Yin T, Little SP, Delapp N, Witkin JM.

Behav Pharmacol. 2011 Sep;22(5-6):531-9. doi: 10.1097/FBP.0b013e328349aace.

PMID:
21836463
23.

A parametric analysis of punishment frequency as a determinant of the response to chlordiazepoxide in the Vogel conflict test in rats.

Gleason SD, Witkin JM.

Pharmacol Biochem Behav. 2007 Aug-Sep;87(3):380-5. Epub 2007 May 24.

PMID:
17583779
24.

Anxiolytic-like effects through a GLUK5 kainate receptor mechanism.

Alt A, Weiss B, Ornstein PL, Gleason SD, Bleakman D, Stratford RE Jr, Witkin JM.

Neuropharmacology. 2007 Jun;52(7):1482-7. Epub 2007 Mar 2.

PMID:
17418283
25.

Effects of dopamine D1 receptor agonists in rats trained to discriminate dihydrexidine.

Gleason SD, Witkin JM.

Psychopharmacology (Berl). 2006 May;186(1):25-31. Epub 2006 Mar 31.

PMID:
16575553
26.

In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders.

Alt A, Weiss B, Ogden AM, Li X, Gleason SD, Calligaro DO, Bleakman D, Witkin JM.

Psychopharmacology (Berl). 2006 Apr;185(2):240-7. Epub 2006 Feb 10.

PMID:
16470401
27.

Effects of dopamine D1 receptor full agonists in rats trained to discriminate SKF 38393.

Gleason SD, Witkin JM.

Behav Pharmacol. 2004 Feb;15(1):85-9.

PMID:
15075630
28.

m-CPP hypolocomotion is selectively antagonized by compounds with high affinity for 5-HT(2C) receptors but not 5-HT(2A) or 5-HT(2B) receptors.

Gleason SD, Lucaites VL, Shannon HE, Nelson DL, Leander JD.

Behav Pharmacol. 2001 Dec;12(8):613-20.

PMID:
11856898
29.

Influence of light cycle on response to 5-HT1A ligands in punished responding in rats.

Gleason SD, Leander JD.

Behav Pharmacol. 1999 Dec;10(8):785-91.

PMID:
10780294
30.
31.

Behavioral pharmacology of olanzapine: a novel antipsychotic drug.

Moore NA, Leander JD, Benvenga MJ, Gleason SD, Shannon H.

J Clin Psychiatry. 1997;58 Suppl 10:37-44. Review.

32.
33.

Nutrient, waste management, and hygiene systems for chemical protective suits.

Cardello AV, Darsch G, Fitzgerald C, Gleason SD, Teixeira R.

Mil Med. 1991 May;156(5):211-5.

PMID:
2057069
34.

Dietary sodium intake: a determinant of postprandial plasma sodium concentration in the dog.

Schneider EG, Gleason SD, Zucker A.

Clin Sci (Lond). 1982 May;62(5):471-7.

PMID:
7075145
35.

Renal and endocrine response to water deprivation in dog.

Zucker A, Gleason SD, Schneider EG.

Am J Physiol. 1982 Mar;242(3):R296-302.

PMID:
7065225
36.

Lack of evidence for gastrointestinal control of sodium excretion in unanesthetized rabbits.

Obika LF, Fitzgerald EM, Gleason SD, Zucker A, Schneider EG.

Am J Physiol. 1981 Feb;240(2):F94-100.

PMID:
7468802
37.

Lack of evidence for gastrointestinal control of sodium excretion in unanesthetized dogs.

Hanson RC, McLane-Vega LA, Childers JW, Gleason SD, Schneider EG.

Am J Physiol. 1980 Feb;238(2):F112-8. No abstract available.

PMID:
7361891

Supplemental Content

Loading ...
Support Center